ReviewHepatology international2018
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Ameer Abutaleb et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled itcites it